Hostname: page-component-78c5997874-dh8gc Total loading time: 0 Render date: 2024-11-05T04:16:57.981Z Has data issue: false hasContentIssue false

Novel Hydroxyapatite-Polysaccharide Composite Microparticles for Immunotherapy

Published online by Cambridge University Press:  14 January 2014

Mitsuhiro Yoshida
Affiliation:
Department of Metallurgy and Ceramics Science, Tokyo Institute of Technology, 2-12-1 Ookayama, Meguro-ku, Tokyo 152-8550 Japan
Tomohiko Yoshioka
Affiliation:
Department of Metallurgy and Ceramics Science, Tokyo Institute of Technology, 2-12-1 Ookayama, Meguro-ku, Tokyo 152-8550 Japan
Toshiyuki Ikoma
Affiliation:
Department of Metallurgy and Ceramics Science, Tokyo Institute of Technology, 2-12-1 Ookayama, Meguro-ku, Tokyo 152-8550 Japan
Junzo Tanaka
Affiliation:
Department of Metallurgy and Ceramics Science, Tokyo Institute of Technology, 2-12-1 Ookayama, Meguro-ku, Tokyo 152-8550 Japan
Get access

Abstract

Hydroxyapatite-chondroitin sulfate (HAp/ChS) composites were synthesized with calcium hydroxide suspension and phosphoric acid solution containing ChS through a precipitation method, and the microparticles were then fabricated by a spray dry method with the suspension of the composites. Bovine serum albumin (BSA) with negative charge or lysozyme (LYZ) with positive charge at pH7.0 was adsorbed onto the HAp/ChS microparticles. However, the HAp/ChS microparticles adsorbed LYZ more than the HAp microparticles compared with BSA due to the electrostatic interaction from negatively-charged sulfate or carboxyl group of ChS in the composites. The release property of BSA from the HAp/ChS microparticles was evaluated in Dulbecco’s phosphate buffered saline (pH7.2). The HAp/ChS microparticles released quickly 100% of the adsorbed BSA, while HAp microparticles released 45% of BSA. These results indicated that incorporation of ChS in the microparticles controls the adsorption and release properties of protein due to the electrostatic interaction. The HAp/ChS microparticles therefore are a candidate of a carrier for drugs like vaccines.

Type
Articles
Copyright
Copyright © Materials Research Society 2014 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

Oka, Y. et al. ., Current Opinion in Immunology 20, 211220 (2008).CrossRefGoogle Scholar
Fong, L. et al. ., Annual review of immunology 18, 245273 (2000).CrossRefGoogle Scholar
Ikeda, H. et al. ., Cancer Science 95, 697703 (2004).CrossRefGoogle Scholar
Chamoto, K. et al. ., Cancer Science 100, 934939 (2009).CrossRefGoogle Scholar
Nagayama, M. et al. ., Dental Materials Journal 25, 219225 (2006).CrossRefGoogle Scholar
Kandori, K. et al. ., Journal of colloid and interface science 273, 406413 (2004).CrossRefGoogle Scholar
Rhee, S.H. et al. ., Journal of Materials Science-Materials in Medicine 13, 597600 (2002).CrossRefGoogle Scholar
Rosenberg, S.A. et al. ., Nature Medicine 10, 909915 (2004).CrossRefGoogle Scholar
Rhee, S.H. et al. ., Journal of the American Ceramic Society 83, 21002102 (2000).CrossRefGoogle Scholar
Koutsopoulos, S., Journal of biomedical materials research 62, 600612 (2002).CrossRefGoogle Scholar
Xiao, X. et al. ., Materials Chemistry and Physics 112, 838843 (2008).CrossRefGoogle Scholar
Wassel, D.T.H. et al. ., Biomaterials 16, 697702 (1995).CrossRefGoogle Scholar
Watanabe, H. et al. ., Key engineering materials 309-311, 533536 (2006).CrossRefGoogle Scholar